Male and Female Contraceptive Development (R43/R44 Clinical Trial Optional)

The summary for the Male and Female Contraceptive Development (R43/R44 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Male and Female Contraceptive Development (R43/R44 Clinical Trial Optional): The purpose of this Funding Opportunity Announcement (FOA) is to invite SBIR applications to support and facilitate the development of new and/or improved contraceptive products for men and women.

Federal Grant Title:	Male and Female Contraceptive Development (R43/R44 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health Income Security and Social Services
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HD-19-004
Type of Funding:	Grant
CFDA Numbers:	93.865
CFDA Descriptions:	Information not provided
Current Application Deadline:	April 16th, 2018
Original Application Deadline:	April 16th, 2018
Posted Date:	February 14th, 2018
Creation Date:	February 14th, 2018
Archive Date:	May 22nd, 2018
Total Program Funding:	$1,500,000
Maximum Federal Grant Award:	$225,000
Minimum Federal Grant Award:
Expected Number of Awards:	6
Cost Sharing or Matching:	No
Last Updated:	February 14th, 2018

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-19-004.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allo...; • National Centers for Translational Research in Reproduction and Infertility (NCTRI) (P50 C...; • Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescen...; • Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed); • Biological Testing Facility (X01 Clinical Trial Not Allowed); • Phase II Small Business Technology Transfer Renewal Awards for Device Assessment or Precli...; • Phase II Small Business Innovation Research Renewal Awards for Device Assessment or Precli...; • Reproductive Genetics and Epigenetics
More Grants from the National Institutes of Health: • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...; • Feasibility Trials of the NIH Music-based Interventions Toolkit for Brain Disorders of Agi...